(Q52760136)

7 May 2018

title

Increased MYC copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma. (English)

1 reference

7 May 2018

2

L Jeffrey Medeiros

1 reference

7 May 2018

Jason R Westin

5

object named as

Jason R Westin

1 reference

7 May 2018

Wei Wang

12

object named as

Wei Wang

1 reference

7 May 2018

author name string

Andrés E Quesada

1

1 reference

7 May 2018

Parth A Desai

3

1 reference

7 May 2018

Pei Lin

4

1 reference

7 May 2018

Huda M Hawsawi

6

1 reference

7 May 2018

Peng Wei

7

1 reference

7 May 2018

Guilin Tang

8

1 reference

7 May 2018

Adam C Seegmiller

9

1 reference

7 May 2018

Nishitha M Reddy

10

1 reference

7 May 2018

C Cameron Yin

11

1 reference

7 May 2018

Jie Xu

13

1 reference

7 May 2018

Roberto N Miranda

14

1 reference

7 May 2018

Zhuang Zuo

15

1 reference

7 May 2018

Shaoying Li

16

1 reference

7 May 2018

publication date

4 August 2017

1 reference

7 May 2018

published in

Modern Pathology

1 reference

7 May 2018

volume

30

1 reference

7 May 2018

issue

12

1 reference

7 May 2018

page(s)

1688-1697

1 reference

7 May 2018

https://scigraph.springernature.com/pub.10.1038/modpathol.2017.93

exact match

0 references

cites work

MYC on the path to cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.93

Reflecting on 25 years with MYC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.93

Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.93

MYC oncogenes and human neoplastic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.93

Mantle cell lymphoma with 8q24 chromosomal abnormalities: a report of 5 cases with blastoid features

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.93

Mantle Cell Lymphoma With MYC Rearrangement: A Report of 17 Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.93

P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.93

MYC translocation in chronic lymphocytic leukaemia is associated with increased prolymphocytes and a poor prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.93

Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.93

MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.93

MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.93

MYC/BCL2 double-hit high-grade B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.93

Prognostic impact of history of follicular lymphoma, induction regimen and stem cell transplant in patients with MYC/BCL2 double hit lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.93

Double-hit B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.93

The 2016 revision of the World Health Organization classification of lymphoid neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.93

Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.93

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.93

Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.93

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Pr

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.93

High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.93

B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.93

MYC cytogenetic status correlates with expression and has prognostic significance in patients with MYC/BCL2 protein double-positive diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.93

CD30 expression and its correlation with MYC rearrangement in de novo diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.93

MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.93

Non-Hodgkin's lymphomas with Burkitt-like cells are associated with c-Myc amplification and poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.93

Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.93

MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.93

Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.93

B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.93

Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.93

Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.93

High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28776574

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/MODPATHOL.2017.93

1 reference

7 May 2018

PubMed ID

28776574

1 reference

7 May 2018